HHS Supports Study of Zika Virus Blood Screening Test
The development of a test to identify whether donated blood is infected with the Zika virus is moving forward with support from the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) and the Office of the Assistant Secretary for Health (OASH).
On March 30, the Food and Drug Administration (FDA) announced the availability of an investigational test to screen blood donations for Zika virus. The test is manufactured by Roche Molecular Systems, Inc., based in Branchburg, N.J.
Today’s agreement with ASPR’s Biomedical Advanced Research and Development Authority (BARDA) supports a clinical study to evaluate the sensitivity and specificity of the blood donation screening test in its actual use. The study is necessary to apply for FDA approval for commercial marketing.
“BARDA staff has worked closely with our partners at FDA and the Office of the Assistant Secretary of Health to ensure the continuity and safety of the U.S. blood supply,” said Dr. Richard Hatchett, BARDA’s acting director. “Today’s award to Roche is an important step toward securing the safety of the blood supply in Puerto Rico and in the rest of the United States.”
Most people infected with Zika do not have symptoms and may donate blood not knowing that they are infected. There have been reports of probable cases of transfusion transmission of Zika virus in Brazil, and those cases currently are being investigated. Having an accurate blood donation screening test will help ensure that infected blood is removed from the blood supply.
Under the one-year, $354,500 contract, Roche will study blood samples to confirm whether the test accurately and reliably detects and identifies Zika virus, even when present in very low concentration in donor blood.
Advancing the development of the Zika virus blood donation screening test is part of BARDA’s integrated portfolio for advanced research and development, innovation, acquisition, and manufacturing of vaccines, drugs, diagnostic tools, and non-pharmaceutical products for public health emergency threats. These threats include chemical, biological, radiological, and nuclear agents, pandemic influenza, emerging infectious diseases, and antimicrobial resistance.
Source: HHS
Unmasking Long COVID: Dr Noah Greenspan on Recovery, Research Gaps, and the Future of Treatment
March 18th 2025Dr Noah Greenspan discusses the evolving understanding of long COVID, current treatment strategies, diagnostic challenges, and the critical need for research and awareness in post-viral syndromes.
Obituary: In Memory of SMART4TB and Project ACCELERATE
March 14th 2025In this remembrance of SMART4TB and Project ACCLERATE, 2 global health initiatives, Heather Stoltzfus, MPH, RN, CIC, explains what they are and why they serve as a warning of what has been lost and what more could be lost in the future.
The Art of Wise Leadership in Infection Control and Quality Management
March 14th 2025Discover how wise leadership in infection control transforms challenges into opportunities, fosters teamwork, and safeguards patient safety through emotional intelligence, strategic vision, and inspiring action.
The CDC at a Crossroads: Budget Cuts, Public Health, and the Growing Threat of Infectious Diseases
March 12th 2025Budget cuts to the CDC threaten disease surveillance, outbreak response, and public health programs, increasing risks from measles, avian flu, and future pandemics while straining health care infrastructure nationwide.
